{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:46:41Z","timestamp":1791956801602,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"DOI":"10.1007\/s13555-026-01956-y","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:45:56Z","timestamp":1791927956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Obesity and Early Biologic Failure in Psoriasis: An Italian Multicentre Retrospective Cohort Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-7649","authenticated-orcid":false,"given":"Jacopo","family":"Tartaglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Donini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Garbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Romagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Schiesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-4733","authenticated-orcid":false,"given":"Stefano","family":"Piaserico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"1956_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CE Griffiths","year":"2007","unstructured":"Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(07)61128-3.","journal-title":"Lancet"},{"key":"1956_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jaad.2008.09.022","volume":"60","author":"SK Kurd","year":"2003","unstructured":"Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2003;60:218\u201324. https:\/\/doi.org\/10.1016\/j.jaad.2008.09.022.","journal-title":"J Am Acad Dermatol"},{"key":"1956_CR3","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","volume":"158","author":"ZZN Yiu","year":"2022","unstructured":"Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, et al. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis. JAMA Dermatol. 2022;158:1131\u201341. https:\/\/doi.org\/10.1001\/jamadermatol.2022.2909.","journal-title":"JAMA Dermatol"},{"key":"1956_CR4","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1111\/jdv.20739","volume":"39","author":"L Motedayen Aval","year":"2025","unstructured":"Motedayen Aval L, Yiu ZZN, Alabas OA, Griffiths CEM, Reynolds NJ, Hampton PJ, et al. Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: a British Association of Dermatologists Biologics and Immunomodulators Register cohort study. J Eur Acad Dermatol Venereol. 2025;39:1785\u201395. https:\/\/doi.org\/10.1111\/jdv.20739.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1956_CR5","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","volume":"23","author":"T Torres","year":"2022","unstructured":"Torres T, Puig L, Vender R, Yeung J, Carrascosa J-M, Piaserico S, et al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23:891\u2013904. https:\/\/doi.org\/10.1007\/s40257-022-00722-y.","journal-title":"Am J Clin Dermatol"},{"key":"1956_CR6","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1038\/nutd.2012.26","volume":"2","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2:e54. https:\/\/doi.org\/10.1038\/nutd.2012.26.","journal-title":"Nutr Diabetes"},{"key":"1956_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195123","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Facciorusso A, Singh AG, Casteele NV, Zarrinpar A, Prokop LJ, et al. Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS ONE. 2018;13:e0195123. https:\/\/doi.org\/10.1371\/journal.pone.0195123.","journal-title":"PLoS ONE"},{"key":"1956_CR8","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/bjd.14552","volume":"175","author":"J Zweegers","year":"2016","unstructured":"Zweegers J, van den Reek JMPA, van de Kerkhof PCM, Otero ME, Kuijpers ALA, Koetsier MIA, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol. 2016;175:340\u20137. https:\/\/doi.org\/10.1111\/bjd.14552.","journal-title":"Br J Dermatol"},{"key":"1956_CR9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jaad.2024.12.016","volume":"92","author":"J Burshtein","year":"2025","unstructured":"Burshtein J, Armstrong A, Chow M, DeBusk L, Glick B, Gottlieb AB, et al. The association between obesity and efficacy of psoriasis therapies: an expert consensus panel. J Am Acad Dermatol Elsevier. 2025;92:807\u201315. https:\/\/doi.org\/10.1016\/j.jaad.2024.12.016.","journal-title":"J Am Acad Dermatol Elsevier"},{"key":"1956_CR10","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","volume":"41","author":"F Pirro","year":"2021","unstructured":"Pirro F, Caldarola G, Chiricozzi A, Burlando M, Mariani M, Parodi A, et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41:917\u201325. https:\/\/doi.org\/10.1007\/s40261-021-01080-z.","journal-title":"Clin Drug Investig"},{"key":"1956_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/jdv.12208","volume":"28","author":"JM Carrascosa","year":"2014","unstructured":"Carrascosa JM, Vilavella M, Garcia-Doval I, Carretero G, Vanaclocha F, Daud\u00e9n E, et al. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm registry. J Eur Acad Dermatol Venereol. 2014;28:907\u201314. https:\/\/doi.org\/10.1111\/jdv.12208.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1956_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jamadermatol.2025.0288","volume":"161","author":"HJ Kim","year":"2025","unstructured":"Kim HJ, Lee E-H, Jung Y. Association of obesity and innate immune markers with resistance to biologic therapy in psoriasis. JAMA Dermatol. 2025;161:629\u201334. https:\/\/doi.org\/10.1001\/jamadermatol.2025.0288.","journal-title":"JAMA Dermatol"},{"key":"1956_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/life11121316","author":"F Anghel","year":"2021","unstructured":"Anghel F, Nitusca D, Cristodor P. Body mass index influence for the personalization of the monoclonal antibodies therapy for psoriasis. Life (Basel). 2021. https:\/\/doi.org\/10.3390\/life11121316.","journal-title":"Life (Basel)"},{"key":"1956_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/0091270008329556","volume":"49","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12\/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49:162\u201375. https:\/\/doi.org\/10.1177\/0091270008329556.","journal-title":"J Clin Pharmacol"},{"key":"1956_CR15","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjd.20971","volume":"186","author":"M Augustin","year":"2022","unstructured":"Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022;186:942\u201354. https:\/\/doi.org\/10.1111\/bjd.20971.","journal-title":"Br J Dermatol"},{"key":"1956_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jbspin.2018.03.007","volume":"86","author":"J Shan","year":"2019","unstructured":"Shan J, Zhang J. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis. Joint Bone Spine. 2019;86:173\u201383. https:\/\/doi.org\/10.1016\/j.jbspin.2018.03.007.","journal-title":"Joint Bone Spine"},{"key":"1956_CR17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.64619","volume":"16","author":"S Eswar","year":"2024","unstructured":"Eswar S, Rajagopalan B, Ete K, Nageswara Rao Gattem S. Serum tumor necrosis factor alpha (TNF-\u03b1) levels in obese and overweight adults: correlations with metabolic syndrome and inflammatory markers. Cureus. 2024;16:e64619. https:\/\/doi.org\/10.7759\/cureus.64619.","journal-title":"Cureus"},{"key":"1956_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/exd.70252","volume":"35","author":"X Shen","year":"2026","unstructured":"Shen X, Wang F, Wang R, Liu H, Dang E, Yu C, et al. Biologic efficacy by BMI in moderate-to-severe psoriasis: a real-world cohort study. Exp Dermatol. 2026;35:e70252. https:\/\/doi.org\/10.1111\/exd.70252.","journal-title":"Exp Dermatol"},{"key":"1956_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70758","author":"J Tartaglia","year":"2026","unstructured":"Tartaglia J, Garbo C, Zanardo E, Alaibac M, Piaserico S. Obesity modifies response to IL-23p19 inhibitors in psoriasis: systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2026. https:\/\/doi.org\/10.1111\/jdv.70758.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1956_CR20","first-page":"706","volume":"14","author":"K Papp","year":"2015","unstructured":"Papp K, Gottlieb AB, Naldi L, Pariser D, Ho V, Goyal K, et al. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol JDD. 2015;14:706\u201314.","journal-title":"J Drugs Dermatol JDD"},{"key":"1956_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22063183","author":"V Guglielmi","year":"2021","unstructured":"Guglielmi V, Colangeli L, D\u2019Adamo M, Sbraccia P. Susceptibility and severity of viral infections in obesity: lessons from influenza to COVID-19. Does leptin play a role? Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22063183.","journal-title":"Int J Mol Sci"},{"key":"1956_CR22","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/1346-8138.16737","volume":"50","author":"T Yanase","year":"2023","unstructured":"Yanase T, Tsuruta N, Yamaguchi K, Ohata C, Ohyama B, Katayama E, et al. Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: a multicenter retrospective study. J Dermatol. 2023;50:753\u201365. https:\/\/doi.org\/10.1111\/1346-8138.16737.","journal-title":"J Dermatol"},{"key":"1956_CR23","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/jid.2015.208","volume":"135","author":"RB Warren","year":"2015","unstructured":"Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker JNWN, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2015;135:2632\u201340. https:\/\/doi.org\/10.1038\/jid.2015.208.","journal-title":"J Invest Dermatol"},{"key":"1956_CR24","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.jid.2017.09.044","volume":"138","author":"IYK Iskandar","year":"2018","unstructured":"Iskandar IYK, Warren RB, Lunt M, Mason KJ, Evans I, McElhone K, et al. Differential drug survival of second-line biologic therapies in patients with psoriasis: observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol. 2018;138:775\u201384. https:\/\/doi.org\/10.1016\/j.jid.2017.09.044.","journal-title":"J Invest Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01956-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01956-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01956-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:02:37Z","timestamp":1791954157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01956-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":24,"alternative-id":["1956"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01956-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"18 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jacopo Tartaglia, Massimo Donini, Carlo Garbo, Alessandro Gatti, Niccol\u00f2 Romagnolo and Lorenzo Schiesari have nothing to disclose. Stefano Piaserico has been a consultant and\/or speaker for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. Paolo Gisondi has been a consultant and\/or speaker for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Janssen, LEO Pharma, Eli Lilly, Novartis, Pierre Fabre, Sandoz, Sanofi, and UCB. Paolo Gisondi is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Paolo Gisondi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required, as this study involved exclusively retrospective data collection from routine clinical care, with no study-specific intervention or deviation from standard clinical practice. The study relied on pre-existing clinical databases maintained at the participating centres as part of routine clinical care. No new patient data were collected for the purposes of the study. The investigators retrospectively extracted the variables required for the present analysis from these existing databases.\u00a0All participants had provided written informed consent for the use of their anonymized clinical data. The study was conducted in accordance with the Declaration of Helsinki and applicable regulations on data protection and patient confidentiality.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}